Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness

Pharmacotherapy

Volumn 27, Issue 4, 2007, Pages 535-541

  Voils, Stacy A ^a   Harpe, Spencer H ^a   Brophy, Gretchen M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anemia; Critical illness; Darbepoetin alfa; Epoetin alfa; Hemoglobin; Recombinant human erythropoietin; rHuEPO; Transfusion; Transfusion independence

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; IRON THERAPY; LENGTH OF STAY; LUNG EMBOLISM; MALE;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; IRON COMPOUNDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRAUMA CENTERS; TREATMENT OUTCOME;

EID: 34047200566     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4.535     Document Type: Article

References (25)

1. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997;23(2):159-62.
2. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986;314(19):1233-5.
3. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999;319(7201):16-19.
4. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002;287:1968-71.
5. Rudis MI, Jacobi J, Hassan E, Dasta JF. Managing anemia in the critically ill patient. Pharmacotherapy 2004;24(2):229-47.
6. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993;269:3024-9.
7. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators. Canadian critical care trials group. N Engl J Med 1999;340(6):409-17.
8. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27(11):2346-50.
9. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288(22):2827-35.
10. Amgen Inc. Aranesp (darbepoetin alfa) package insert. Thousand Oaks, CA; 2003.
11. Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167-75.
12. Seidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Rockville, MD: Agency for Healthcare Research and Quality. May 23, 2006. Available from http://effectivehealthcare.ahrq.gov/repFiles/EPO %20Final.pdf. Accessed September 15, 2006.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13(10):818-29.
14. Macdougall IC. Optimizing the use of erythropoietic agents-pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17(suppl 5)66-70.
15. Ortho Biotech Products, L.P. Procrit (epoetin alfa) package insert. Bridgewater, NJ; 2005.
16. United States Food and Drug Administration. 2007 safety alert: Aranesp (darbepoetin alfa). Available from www.fda.gov/medwatch/safety/2007/ aranesp_DHCP_012707.htm. Accessed February 14, 2007.
17. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med 2004;32(1):39-52.
18. Marino PL. The ICU book, 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins; 1998:731-2.
19. Pieracci FM, Barie PS. Iron and the risk of infection. Surg Infect 2005;6:S41-6.
20. Pieracci FM, Barie PS. Diagnosis and management of iron-related anemias. Crit Care Med 2006;34:1898-905.
21. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2002;345(19):1368-77.
22. Freudenberger RS, Carson JL. Is there an optimal hemoglobin value in the cardiac intensive care unit? Curr Opin Crit Care 2003;9(5):356-61.
23. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29(2):227-34.
24. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292(13):1555-62.
25. Hebert PC, Fergusson DA, Stather D, et al. Revisiting transfusion practices in critically ill patients. Crit Care Med 2005;33(1):7-12.